SCHEMBL27436775

SCHEMBL27436775

COc1ccc2c(n1)CCN2C(=O)CCl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 3/20 0.44
CASP3 P42574 2/20 0.44
MTNR1A P48039 4/20 0.36
MTNR1B P49286 4/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
IDO1 P14902 1/20 0.36
NOTUM Q6P988 2/20 0.36
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NPC1 O15118 2/20 0.35
MAPK1 P28482 1/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MITF O75030 1/20 0.35
XBP1 P17861 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23063858 0.70 CYP11B1 (0.43) SMN1; SMN2MAPTKDM4EALDH1A1GRM5
SCHEMBL23817954 0.68 ALDH1A1 (0.50) CASP2CASP3RAB9ASMN1; SMN2NOTUM
SCHEMBL21107652 0.67 HSD17B10 (0.70) SMN1; SMN2NOTUMMAPTKDM4EMEN1
SCHEMBL19126914 0.67 GRM5 (0.49) MTNR1AMTNR1BGRM5
SCHEMBL6124247 0.66 IDO1 (0.43) IDO1MAPTKDM4EALDH1A1POLB
SCHEMBL7240958 0.66 HSD17B10 (0.45) MTNR1AMTNR1BRAB9ASMN1; SMN2NOTUM
SCHEMBL6073495 0.65 CYP11B2 (0.42) RAB9ASMN1; SMN2NPC1LMNAPOLB
SCHEMBL4008920 0.65 GRM5 (0.53) MTNR1AMTNR1BKDM4EMEN1KMT2A
SCHEMBL23063856 0.64 MAPT (0.42) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1928973 0.64 TSHR (0.75) CASP3RAB9ASMN1; SMN2NOTUMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024133499-A1 GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) 2024-06-27 WO disclosed